Long-Lasting Response to Trabectedin in a Patient with Metastatic Uterine Leiomyosarcoma: A Case Report
Conclusion: Trabectedin seems to be an efficient option for patients with uLMS as demonstrated by a long-lasting response in a pretreated patient with an acceptable safety profile with no signs of cumulative toxicity.Case Rep Oncol 2018;11:81 –89
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
More News: Bleeding | Cancer & Oncology | Chemotherapy | CT Scan | Hysterectomy | Leiomyosarcoma | PET Scan | Toxicology